Key results:
- Created a dedicated group of R&D personnel that can focus on new product innovations
- Re-defined our R&D portfolio and find the right partners
- Clarified how to pursue with Surgical Perfusion and how to approach ECCO2R
- Investigated where the Cardiopulmonary market will develop
- Re-defined / adjusted clinical and commercial strategy, R&D development portfolio and our internal capacities accordingly
- Identified “blind spots” within R&D projects that hinder progressing rapidly
- Identified the right external experts and technology partners